Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 1Thyroid Diseases 1Solid Tumors 1Prostatic Neoplasms 1Neoplasms 1Melanoma 1Lymphoma 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Sorafenib 3selpercatinib 2cabozantinib 2Thyroid (USP) 2Sodium 2Radiofrequency Ablation 2Metformin 2vandetanib 1tomivosertib 1temsirolimus 1repotrectinib 1pralsetinib 1pembrolizumab 1lenvatinib 1binimetinib 1apatinib 1acetaminophen, codeine drug combination 1Vitamin B 12 1Tramadol 1Thyroxine 1Thyrotropin-Releasing Hormone 1Technetium Tc 99m Sestamibi 1Surgical Procedures, Operative 1Pemetrexed 1Panobinostat 1Negative-Pressure Wound Therapy 1NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt 1Lysine Acetyltransferase 5 1Iodine-131 1Folic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thyroid Diseases × tomivosertib × Clear all
NCT02605083 2020-11-02

A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

Effector Therapeutics

Phase 1/2 Terminated
66 enrolled
DermatologicHead & Neck

Melanoma, Neoplasms, Thyroid Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡